Plain-English translation of NCT06530550 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing two medications—Linperlisib or Duvelisib—to see if they can help treat T-cell and NK-cell lymphomas that have come back or stopped responding to previous treatments. These are rare blood cancers of immune cells, and this medication works by blocking a specific protein that helps cancer cells grow. The study will enroll 51 patients and track how well the medication works over up to two years.
Many patients with these types of lymphomas eventually stop responding to standard treatments, and there are limited options available to help them. This trial is exploring whether this medication can offer hope to patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
You will take one of two medications by mouth every day in 28-day cycles for up to two years. During the first year, you'll have check-in visits with your doctor once per cycle to see how the medication is working and check for side effects. After that, visits become less frequent. Your treatment will continue unless the cancer gets worse, it doesn't respond within the first 6 months, or you develop side effects that are too difficult to manage.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China